New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.

Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

Alpha-Gal Syndrome (AGS) is an underrecognized, tick-borne allergic condition with emerging relevance in cardiovascular medicine. Sensitization to galactose-α-1,3-galactose (alpha-gal), a ...

A small study identified potential immunologic patterns associated with post-vaccination syndrome, a very rare condition with neurologic symptoms that occurs in some people following a COVID-19 ...

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) ...

Gareth Bayley had a stroke in his brain stem when he was 38 — triggering locked-in syndrome, a devastating condition that his wife Karen explains as being "trapped in his own body” Those with ...

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical ...

The Prognostic Nutritional Index and systemic oxidative stress score are independently associated with poorer prognosis of low-risk MDS.

Abstract/Full Text Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome Young man visiting his wife with cancer indoors ...